Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7259   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004527-16
    Sponsor's Protocol Code Number:1425-0003
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-09-29
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-004527-16
    A.3Full title of the trial
    A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment
    Sperimentazione di fase IIa, randomizzata, in doppio cieco, controllata con placebo, volta a valutare la sicurezza, l’efficacia, la farmacocinetica e la farmacodinamica di BI 706321 somministrato per via orale per 12 settimane in pazienti affetti da morbo di Crohn (MC) che ricevono il trattamento di induzione con ustekinumab
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to test whether BI 706321 combined with ustekinumab helps people with Crohn’s Disease
    Uno studio per verificare se BI 706321 combinato con ustekinumab aiuta le persone con morbo di Crohn
    A.3.2Name or abbreviated title of the trial where available
    InCharge
    InCharge
    A.4.1Sponsor's protocol code number1425-0003
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBOEHRINGER INGELHEIM INTERNATIONAL GMBH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBoehringer Ingelheim International GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBoehringer Ingelheim International GmbH
    B.5.2Functional name of contact pointCT Disclosure & Data Transparency
    B.5.3 Address:
    B.5.3.1Street AddressBinger Strasse 173
    B.5.3.2Town/ cityIngelheim am Rhein
    B.5.3.3Post code55216
    B.5.3.4CountryGermany
    B.5.4Telephone number00498002430127
    B.5.5Fax number00498008217119
    B.5.6E-mailclintriage.rdg@boehringer-ingelheim.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Stelara 130mg / 26mL concentrate for solution for infusion
    D.2.1.1.2Name of the Marketing Authorisation holderJANSSEN-CILAG INTERNATIONAL NV
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameStelara 130mg / 26mL concentrate for solution for infusion
    D.3.2Product code [Stelara 130mg / 26mL concentrate for solution for
    D.3.4Pharmaceutical form Concentrate for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNUSTEKINUMAB
    D.3.9.1CAS number 815610-63-0
    D.3.9.2Current sponsor codeustekinumab
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBI 706321
    D.3.2Product code [BI 706321]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 2205041-37-6
    D.3.9.2Current sponsor codeBI 706321 XX
    D.3.9.4EV Substance CodeSUB197459
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBI 706321
    D.3.2Product code [BI 706321]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 2205041-37-6
    D.3.9.2Current sponsor codeBI 706321 XX
    D.3.9.4EV Substance CodeSUB197459
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBI 706321
    D.3.2Product code [BI 706321]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 2205041-37-6
    D.3.9.2Current sponsor codeBI 706321 XX
    D.3.9.4EV Substance CodeSUB197459
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name STELARA - 90 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) 1 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 1 ML
    D.2.1.1.2Name of the Marketing Authorisation holderJANSSEN-CILAG INTERNATIONAL N.V.
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameStelara 90mg/1ml solution for injection in pre-filled syringe (PFS)
    D.3.2Product code [Stelara 90mg/1ml solution for injection in pre-fi
    D.3.4Pharmaceutical form Concentrate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNUSTEKINUMAB
    D.3.9.1CAS number 815610-63-0
    D.3.9.2Current sponsor codeustekinumab
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number90
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 3
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Crohn`s Disease (CD)
    Morbo di Crohn (MB)
    E.1.1.1Medical condition in easily understood language
    Crohn`s Disease is a gastrointestinal disease
    Il morbo di Crohn è una malattia gastrointestinale
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10011401
    E.1.2Term Crohn's disease
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The main objectives of this trial are to investigate a first signal of efficacy, safety and tolerability of BI 706321 in combination with ustekinumab treatment compared to placebo with ustekinumab treatment in patients with moderately to severely active CD at 12 weeks.

    The primary objective is to estimate the difference in change from baseline in Simple Endoscopic Score for Crohn’s disease (SES-CD) after 12 weeks. The primary treatment comparison will be between treatment groups while on treatment during the 12 week induction period.
    Gli obiettivi principali di questo studio sono studiare un primo segnale di efficacia, sicurezza e tollerabilità di BI 706321 in combinazione con il trattamento con ustekinumab rispetto al placebo con il trattamento con ustekinumab in pazienti con MC attivo da moderato a grave a 12 settimane.

    L'obiettivo primario è stimare la differenza di variazione rispetto al basale nel punteggio endoscopico semplice per il morbo di Crohn (SES-CD) dopo 12 settimane. Il confronto del trattamento primario sarà tra i gruppi di trattamento durante il trattamento durante il periodo di induzione di 12 settimane.
    E.2.2Secondary objectives of the trial
    Not applicable
    Non applicabile
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or female patients.
    2. = 18 – = 75 years, at date of signing informed consent.
    3. Diagnosis of CD for at least 3 months prior to visit 1 by endoscopic, radiology, and supported by histology.
    4. Elevated CRP (= 5 mg/L) OR elevated fecal calprotectin (= 250 µg/g)
    5. Moderate to severe active CD at visit 1 defined as CDAI =220 and =450 (one rescreening is allowed).
    6. Presence of mucosal ulcers in at least one segment of the ileum or colon and a SESCD score = 7 (for patients with isolated ileitis =4), as assessed by ileo-colonoscopy and confirmed by central independent reviewer(s) before start of study treatment.
    7. Patients who are experienced to 1 or 2 TNF antagonists (i.e. biosimilars of a drug are counted as the originator drug, e.g. the switch from infliximab originator to CT-P13 will count as one TNF antagonist exposure) at a dose approved for CD. Patients may have stopped TNF antagonists treatment due to primary or secondary nonresponsiveness, intolerance (see definitions in Appendix 10.7), or for other reasons.
    8. May be receiving a therapeutic dose of the following:
    o Oral 5-ASA compounds must have been at a stable dose for at least 4 weeks prior to randomisation and must continue on this dose until week 12 and/or
    o Oral corticosteroids if indicated for treatment of CD must be at a prednisone equivalent dose of = 20 mg/day, or = 9 mg/day of budesonide, and have been at a stable dose for at least 2 weeks immediately prior to randomisation and must continue on this dose until week 12. [Allowed steroid treatments: Locally administered steroids as e.g. intra-articular, nasal inhalation or intra-ocular
    administration are allowed.] and/or
    o AZA, MP, or MTX, provided that dose has been stable for the 8 weeks immediately prior to randomisation and must continue on this dose until week 12.
    9. Women of childbearing potential (WOCBP)1 must be ready and able to use highly effective methods of birth control per International Councila on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information or in Section 4.2.2.3.
    10. Signed and dated written informed consent in accordance with ICH- Good Clinical Practice (GCP) and local legislation prior to admission to the trial.
    1. Pazienti di sesso maschile o femminile.
    2. = 18 – = 75 anni, alla data di sottoscrizione del consenso informato.
    3. Diagnosi di MC per almeno 3 mesi prima della visita 1 mediante endoscopica, radiologia e supportata da istologia.
    4. CRP elevata (= 5 mg/L) O calprotectina fecale elevata (= 250 µg/g)
    5. CD attivo da moderato a severo alla visita 1 definito come CDAI =220 e =450 (è consentito un nuovo screening).
    6. Presenza di ulcere della mucosa in almeno un segmento dell'ileo o del colon e punteggio SESCD = 7 (per i pazienti con ileite isolata = 4), come valutato mediante ileocolonscopia e confermato da revisori indipendenti centrali prima dell'inizio del trattamento in studio.
    7. I pazienti che hanno esperienza con 1 o 2 antagonisti del TNF (cioè i biosimilari di un farmaco sono conteggiati come farmaco originatore, ad es. I pazienti possono aver interrotto il trattamento con antagonisti del TNF a causa di non responsività primaria o secondaria, intolleranza (vedere le definizioni nell'Appendice 10.7) o per altri motivi.
    8. Può ricevere una dose terapeutica di quanto segue:
    o I composti 5-ASA orali devono essere stati a una dose stabile per almeno 4 settimane prima della randomizzazione e devono continuare con questa dose fino alla settimana 12 e/o
    o I corticosteroidi orali, se indicati per il trattamento del MC, devono essere a una dose equivalente di prednisone di = 20 mg/die, o = 9 mg/die di budesonide, e sono stati a una dose stabile per almeno 2 settimane immediatamente prima della randomizzazione e devono continuare con questa dose fino alla settimana 12. [Trattamenti con steroidi consentiti: steroidi somministrati localmente come ad es intra-articolare, inalazione nasale o intra-oculare
    amministrazione sono consentiti.] e/o
    o AZA, MP o MTX, a condizione che la dose sia rimasta stabile per le 8 settimane immediatamente precedenti la randomizzazione e debba continuare con questa dose fino alla settimana 12.
    9. Le donne in età fertile (WOCBP)1 devono essere pronte e in grado di utilizzare metodi di controllo delle nascite altamente efficaci secondo l'International Councila on Harmonization (ICH) M3 (R2) che si traduca in un basso tasso di fallimento inferiore all'1% all'anno quando utilizzato in modo coerente e corretto. Un elenco di metodi contraccettivi che soddisfano questi criteri è fornito nelle informazioni per il paziente o nella Sezione 4.2.2.3.
    10. Consenso informato scritto firmato e datato in conformità con ICH- Good Clinical Practice (GCP) e la legislazione locale prima dell'ammissione allo studio.
    E.4Principal exclusion criteria
    1. Have any current or prior abscesses, unless they have been drained and treated at least 6 weeks prior to randomisation and are not anticipated to require surgery. Patients with active fistulas may be included if there is no anticipation of a need for surgery and there are currently no abscesses present based on investigator`s judgement.
    2. Have complications of CD such as strictures, stenosis, short bowel syndrome, or any other manifestation that might require surgery, or could preclude the use of SESCD/ CDAI to assess response to therapy, or would possibly confound the evaluation of benefit from treatment with BI 706321 (based on investigator’s judgement).
    3. Patient with an inflammatory bowel disease (IBD) diagnosis other than CD.
    4. Have had any kind of bowel resection or diversion within 4 months or any other intraabdominal surgery within 3 months prior to visit 1. Patients with current ileostomy, colostomy, or ileorectal anastomosis are excluded.
    5. Treatment with:
    o any non-biologic medication for IBD (e.g.tacrolimus or mycophenolate mofetil, systemic corticosteroids), other than those allowed per inclusion criteria, within 30 days prior to randomisation
    o any biologic treatment with a TNF-alpha antagonist (adalimumab, infliximab, golimumab, certolizumab pegol) or vedolizumab within 4 weeks prior to randomisation. (If drug level testing for previously used biologic treatment confirms no detectable drug level before randomisation, patient can be enrolled despite not having completed 4 week from last treatment.)
    o any previous treatment with ustekinumab
    o any previous treatment with an investigational non-biologic or biologic drug for CD (including but not limited to JAK inhibitors, S1P modulators, IL-23 inhibitors, anti-integrins).
    o any investigational drug for an indication other than CD during the course of the actual study and within 30 days or 5 half-lives (whichever is longer) prior to randomisation.
    o any prior exposure to rituximab within 1 year prior to randomisation.
    6. Positive stool examination for C difficile (toxin A/B – test positive) or other intestinal pathogens <30 days prior to randomisation. Re screening can be undertaken following documented successful treatment, no sooner than 1 week after last intake of antimicrobial therapy.
    7. Evidence of colonic moderate/severe mucosal dysplasia or colonic adenomas, unless properly removed.
    8. Fecal transplant = 30 days prior to randomisation.
    9. Increased risk of infectious complications (e.g. recent pyogenic infection, any congenital or acquired immunodeficiency (e.g. Human immunodeficiency virus (HIV)), past organ or stem cell transplantation (with exception of a corneal transplant > 12 weeks prior to screening) or have ever received stem cell therapy (e.g., Prochymal). Prior treatment with a somatic cell therapy product (e.g., Alofisel) is not excluded, provided it was administered > 8 weeks prior to randomisation.
    10. Live or attenuated vaccination within 4 weeks prior to randomisation.
    11. Have received BCG vaccines = 1 year prior to randomisation.
    12. Active or latent TB:
    o Patients with active tuberculosis are excluded.
    o Patients will be screened with Interferon Gamma Release Assay (IGRA) such as QuantiFERON or T spot, the patient may also be evaluated for the presence of TB with any additional test required by local practice. Patients with positive test results are excluded unless patient is known to have had a previous diagnosis of active or latent TB and has completed appropriate treatment per local practice/guidelines within the last 3 years and at least 6 months before first administration of trial medication under this protocol (patients may be rescreened once to meet this specific criterion)
    o Patients with indeterminate QuantiFERON or invalid/borderline T spot may be re-tested with IGRA (once), and if again inconclusive, should have a Purified Protein Derivative (PPD) skin test.
    ...
    1. Avere ascessi in corso o precedenti, a meno che non siano stati drenati e trattati almeno 6 settimane prima della randomizzazione e non si prevede che richiedano un intervento chirurgico. I pazienti con fistole attive possono essere inclusi se non si prevede la necessità di un intervento chirurgico e non sono attualmente presenti ascessi in base al giudizio dello sperimentatore.
    2. Avere complicanze della MC come stenosi, stenosi, sindrome dell'intestino corto o qualsiasi altra manifestazione che potrebbe richiedere un intervento chirurgico, o potrebbe precludere l'uso di SESCD/CDAI per valutare la risposta alla terapia, o potrebbe confondere la valutazione del beneficio del trattamento con BI 706321 (basato sul giudizio dell'investigatore).
    3. Paziente con diagnosi di malattia infiammatoria intestinale (IBD) diversa da MC.
    4. Hanno subito qualsiasi tipo di resezione o diversione intestinale nei 4 mesi o qualsiasi altro intervento chirurgico intraddominale nei 3 mesi precedenti la visita 1. Sono esclusi i pazienti con ileostomia, colostomia o anastomosi ileorettale in corso.
    5. Trattamento con:
    o qualsiasi farmaco non biologico per IBD (es. tacrolimus o micofenolato mofetile, corticosteroidi sistemici), diversi da quelli consentiti dai criteri di inclusione, entro 30 giorni prima della randomizzazione
    o qualsiasi trattamento biologico con un antagonista del TNF-alfa (adalimumab, infliximab, golimumab, certolizumab pegol) o vedolizumab nelle 4 settimane precedenti la randomizzazione. (Se il test del livello del farmaco per il trattamento biologico utilizzato in precedenza conferma che nessun livello del farmaco rilevabile prima della randomizzazione, il paziente può essere arruolato nonostante non abbia completato 4 settimane dall'ultimo trattamento.)
    o qualsiasi precedente trattamento con ustekinumab
    o qualsiasi precedente trattamento con un farmaco sperimentale non biologico o biologico per la MC (inclusi ma non limitati a inibitori JAK, modulatori S1P, inibitori di IL-23, anti-integrine).
    o qualsiasi farmaco sperimentale per un'indicazione diversa dalla MC nel corso dello studio effettivo ed entro 30 giorni o 5 emivite (a seconda di quale sia più lunga) prima della randomizzazione.
    o qualsiasi precedente esposizione a rituximab entro 1 anno prima della randomizzazione.
    6. Esame delle feci positivo per C difficile (tossina A/B – test positivo) o altri patogeni intestinali <30 giorni prima della randomizzazione. Il nuovo screening può essere effettuato dopo un trattamento di successo documentato, non prima di 1 settimana dopo l'ultima assunzione di terapia antimicrobica.
    7. Evidenza di displasia della mucosa del colon moderata/grave o adenomi del colon, se non adeguatamente rimossi.
    8. Trapianto fecale = 30 giorni prima della randomizzazione.
    9. Aumento del rischio di complicanze infettive (ad es. infezione piogenica recente, qualsiasi immunodeficienza congenita o acquisita (ad es. virus dell'immunodeficienza umana (HIV)), trapianto di organi o cellule staminali pregresso (ad eccezione di un trapianto di cornea > 12 settimane prima dello screening) o avere mai ricevuto una terapia con cellule staminali (ad es. Prochymal) Non è escluso un precedente trattamento con un prodotto di terapia cellulare somatica (ad es. Alofisel), a condizione che sia stato somministrato > 8 settimane prima della randomizzazione.
    10. Vaccinazione viva o attenuata nelle 4 settimane precedenti la randomizzazione.
    11. Hanno ricevuto vaccini BCG = 1 anno prima della randomizzazione.
    12. TBC attiva o latente:
    o Sono esclusi i pazienti con tubercolosi attiva.
    ...
    E.5 End points
    E.5.1Primary end point(s)
    Absolute change from baseline in Simple Endoscopic Score for Crohn’s disease (SES-CD) at week 12.
    Variazione assoluta dal basale del punteggio endoscopico semplice per il morbo di Crohn (SES-CD) alla settimana 12.
    E.5.1.1Timepoint(s) of evaluation of this end point
    12 weeks
    12 settimane
    E.5.2Secondary end point(s)
    Secondary endpoints:
    - Percent change in SES-CD from baseline at Week 12
    - Endoscopic response (defined as =50% SES-CD reduction from baseline) at Week 12
    - Endoscopic response (defined as =50% SES-CD reduction from baseline) at Week 48
    - Endoscopic remission (defined as SES-CD score of =2) at week 12
    - Endoscopic remission (defined as SES-CD score of =2) at week 48.
    - Biological remission, defined as C-reactive protein (CRP) <5 mg/L and faecal calprotectin (FCP) < 250 ug/g at week 12
    - Biological remission, defined as CRP < 5 mg/L and FCP <250 ug/g at week 48
    - Clinical remission at week 12, defined as a Crohn’s Disease Activity Index (CDAI) score of <150
    - Clinical remission at week 48, defined as a CDAI score of<150
    - Clinical response at week 12, defined by a CDAI reduction from baseline of at least 100 points, or a CDAI score of <150
    - Number of patients with treatment-emergent adverse event(TEAE) through end of treatment (EoT) and the residual effect period (REP) (i.e. through Visit 9)
    Endpoint secondari:
    - Variazione percentuale di SES-CD rispetto al basale alla settimana 12
    - Risposta endoscopica (definita come =riduzione SES-CD del 50% rispetto al basale) alla settimana 12
    - Risposta endoscopica (definita come =riduzione SES-CD del 50% rispetto al basale) alla settimana 48
    - Remissione endoscopica (definita come punteggio SES-CD di =2) alla settimana 12
    - Remissione endoscopica (definita come punteggio SES-CD di =2) alla settimana 48.
    - Remissione biologica, definita come proteina C-reattiva (CRP) <5 mg/L e calprotectina fecale (FCP) < 250 ug/g alla settimana 12
    - Remissione biologica, definita come CRP < 5 mg/L e FCP <250 ug/g alla settimana 48
    - Remissione clinica alla settimana 12, definita come un punteggio del Crohn's Disease Activity Index (CDAI) di <150
    - Remissione clinica alla settimana 48, definita come un punteggio CDAI di <150
    - Risposta clinica alla settimana 12, definita da una riduzione CDAI dal basale di almeno 100 punti, o un punteggio CDAI <150
    - Numero di pazienti con evento avverso emergente dal trattamento (TEAE) fino alla fine del trattamento (EoT) e al periodo dell'effetto residuo (REP) (ovvero fino alla visita 9)
    E.5.2.1Timepoint(s) of evaluation of this end point
    48 weeks
    48 settimane
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA34
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    Belgium
    France
    Italy
    Poland
    Spain
    Czechia
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last visit of the last patient in the whole trial ("Last Patient Completed").
    Ultima visita dell'ultimo paziente dell'intero studio ("Last Patient Completed").
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 45
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 5
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 34
    F.4.2.2In the whole clinical trial 50
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-12-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-10-21
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA